arrow
M

Matthew C. Foster

University System of Ohio
H指数:23
被引数:2,961

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML

评估enasidenib和适应风险的阿扎胞苷添加对新诊断的IDH2-mutant AML的疗效的研究

2024-01-127
OAAI
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
2023-05-258
OAAI
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Entospletinib联合地西他滨治疗TP53突变或复杂核型的急性髓系白血病: Beat AML Master试验的2期子研究

CANCER
IF5.1
2023-04-207
PRE
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia

异基因造血干细胞移植前应用帕博利珠单抗治疗急性髓系白血病的安全性和有效性

2021-12-0116
OAAI
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
2021-09-1053
OA
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
2020-10-26111
OAAI
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
LEUKEMIA
IF13.4
2020-01-0318
OAAI